ABSTRACT
Objective: To study therapeutic effect and influence of fluvastatin combined arotinolol on serum levels of growth differentiation factor 15 (GDF-15) and neutrophil gelatinase associated lipocalin (NGAL) in patients with coronary heart disease (CHD) complicated heart failure (HF). Methods: A total of 140 CHD + HF patients, who were treated in our department of cardiology from May 2013 to May 2015, were selected. According to random number table, patients were randomly and equally divided into arotinolol group and combined treatment group (received fluvastatin based on arotinolol group), both groups were treated for three months. Therapeutic effect, left ventricular end-diastolic dimension (LVEDd), end-diastolic interventricular septal thickness (IVSTd), left ventricular ejection fraction (LVEF), mean arterial pressure (MAP), cardiac index (CI), stroke index (SI), stroke volume (SV), serum levels of GDF-15 and NGAL before and after treatment were compared between two groups. Results: Compared with arotinolol group after treatment, there were significant rise in LVEF [(45. 31±6. 73) ％ vs. (72. 64±7. 29) ％], MAP [(59. 34±6. 93) mmHg vs. (75. 61±7. 24) mmHg], CI [(2. 66±1. 31) L/min2 vs. (3. 12± 1. 37) L/min2], SI [(27. 15±4. 37) ml/m2 vs. (49. 81±5. 79) ml/m2]and SV [(60. 99±5. 13) ml vs. (71. 24± 5. 94) ml], and significant reductions in IVSTd [(13. 51±3. 17) mm vs. (11. 27±7. 26) mm], serum levels of GDF-15 [(1153. 4±153. 7) ng/L vs. (923. 8±81. 4) ng/L]and NGAL [(112. 52±61. 49) μg/L vs. (78. 14± 35. 74) μg/L]in combined treatment group (P＜0. 05 or＜0. 01). Total effective rate of combined treatment group was significantly higher than that of arotinolol group (87. 14％ vs. 74. 29％), P=0. 007. Conclusion: Fluvastatin combined arotinolol can effectively improve heart function, significantly reduce serum GDF-15 and NGAL levels, and improve prognosis in CHD + HF patients, which is worth extending.
ABSTRACT
Objective:To study therapeutic effect of arotinolol hydrochloride on chronic heart failure (CHF) and its influence on plasma levels of brain natriuretic peptide (BNP).Methods:A total of 116 CHF patients treated in our hospital were selected,randomly and equally divided into routine treatment group and arotinolol group (received arotinolol based on routine treatment ),both groups were continuously treated for six months.Left ventricular end-systolic volume (LVESV ),left ventricular end-diastolic volume (LVEDV ),left ventricular ejection fraction (LVEF),myocardial energy expenditure (MEE),serum levels of interleukin (IL)-8 and high sensitive C reactive protein (hsCRP),plasma BNP level,Lee heart failure score and incidence of adverse reactions were observed and compared between two groups before and after treatment.Results:Compared with routine treatment group after treatment,there were significant reductions in LVESV [ (38.45 ± 3.93) ml vs.(36.42 ± 3.51) ml],LVEDV [ (49.23 ± 4.89) ml vs.(47.43 ± 4.37) ml],MEE [ (96.11 ± 9.86) cal/min vs.(86.58 ± 8.83) cal/min],levels of IL-8 [ (32.18 ± 3.17) ng/L vs.(28.92 ± 2.79) ng/L],hsCRP [ (5.86 ± 0.51) mg/L vs.(3.78 ± 0.35) mg/L],BNP [ (275.75 ± 27.64) ng/L vs.(196.75 ± 20.04) ng/L] and Lee heart failure score [ (4.77 ± 0.73) scores vs.(2.82 ± 0.54) scores],and significant rise in LVEF [ (45.69 ± 4.76)% vs.(51.89 ± 5.30)%] in arotinolol group,P＜0.05 or ＜0.01.Total effective rate of arotinolol group was significantly higher than that of routine treatment group (94.83% vs.79.31%,P＝0.027).There were no obvious adverse reactions in two groups during treatment.Conclusion:Arotinolol can significantly improve heart function,reduce plasma BNP and inflammatory factor levels in CHF patients.The therapeutic effect is significant,and it＇s safe and reliable.
ABSTRACT
ABSTRACT:Objective To study the effects of arotinolol,propranolol and carvedilol on rat portal hypertension and make a comprehensive evaluation of the three drugs.Methods Portal hypertension was induced with CCl4 in rats.Arotinolol,propranolol,and carvedilol were administered for 2 weeks after the model was stable.Mean arterial pressure (MAP),heart rate (HR)and portal venous pressure (PVP)were measured at intubation;α-SMA expression was measured by immunohistochemistry;Masson staining was used to test collagen fibers area.Results Compared with model group,both arotinolol and carvedilol could significantly reduce PVP level (P significantly declined compared with those in model group (P <0.05 ).Conclusion Arotinolol can significantly reduce cirrhotic rats’ portal pressure,with effects similar to those of carvedilol.The effect of arotinolol in improving liver function is weaker than that of carvedilol,but the side effects on MAP are milder than those of carvedilol.
ABSTRACT
Objective Dilated cardiomyopathy (DCM) is generally considered to be accompanied by both left and right ventricular dysfunction,but most studies only analyze the left ventricular function. In this study, we evaluated the effect of arotinolol on right ventricular function in patients with DCM. Methods Right ventricular ejection fraction (RVEF) and right ventricular diameter (RVD) were measured by two-dimensional echocardiography (2-DE) in 33 DCM patients; RVEF measured by first-pass radionuclide angiography (FPRA) was compared with that by 2-DE. Results The treatment with arotinolol for one year resulted in a reduction in the right ventricular diameter (baseline, 23.0 ± 8.3 mm vs after one-year treatment, 20.7 ± 5.4 mm; P=0.004 ) and an associated increase in ejection fraction (baseline, 36.9 ± 10.3% vs after one-year treatment, 45.8 ± 9.6%; P ＜ 0.001 ); there is a high correlation between the 2-DE method and radionuclide ventriculographic method. The correlation coefficient is 0.933 (P＜0.001). Conclusion Arotinolol therapy could not only improve left ventricular function, but also improve right ventricular function in DCM patients.
ABSTRACT
Objective To approach the efficacy and safety of arotinolol in treating essential hypertension.Methods The studies about arotinolol in treating essential hypertension were accessed by searching the Cochrane Central Register of Controlled Trials(Issue 3,2008),MEDLINE(1991 to March 2009),EMbase(1991 to March 2009),CBMdisc(1991 to March 2009),and CNKI(1994 to March 2009).The relevant journals and conference proceedings also hand searched.Randomized controlled trials(RCTs) in which arotinolol was used to treat patients with essential hypertension were collected.Then the retrieved studies according to predefined inclusion and exclusion criteria were screened,the quality of included studies was evaluated,and Meta analysis was performed by using RevMan 4.2 software.Results A total of 176 articles were found and 6 of which were finally included.In homogeneity test:?2=4.41,df=7,P=0.73(efficacy);?2=2.96,df=4,P=0.56(safety).In combined test,Z=0.64(P=0.52),OR=1.17,OR95%CI(0.72-1.85)(efficacy);Z=1.75(P=0.08),OR=0.60,OR95%CI(0.34-1.06)(safety).Conclusion There is no significant difference in efficacy and safety between arotinolol and control group in treating essential hypertension.
ABSTRACT
To evaluate the antihypertensive effect, side effects and metabolic changes of arotinolol, a combined alpha and beta blocker, 10-15mg of arotinolol twice a day was administered for 8 weeks in 27 hypertensives (168+/-16/106+/-10mmHg) without heart failure, bradycardia, conduction disturbance, coronary heart disease or renal impairment. Blood pressure decreased to 137+/-10/90+/-6mmHg and average reduction of systolic BP and diastolic BP were 31 mmHg(18%) and 16mmHg(15%) respectively. Pulse rate reduced significantly(p<0.01) after 2weeks' treatment of arotinolol and average reduction of pulse rate was 10 beats/min after 8weeks treatment. There were no significant changes of serum ALP, AST and ALT, BUN, and serum creatinine, Na+, K+, total cholesterol, HDL cholesterol and triglyceride. But in 8 patients(30%), insomina, sleepness, cold extrimities or numbness on extremities developed or aggravated. These results suggest that arotinolol be an useful antihypertensive agent in hypertensives without heart failure, bradyarrhythmais or peripheral vascular disease.
Subject(s)
Blood Pressure , Bradycardia , Cholesterol , Cholesterol, HDL , Coronary Disease , Creatinine , Extremities , Heart Failure , Heart Rate , Hypertension , Hypesthesia , Peripheral Vascular Diseases , TriglyceridesABSTRACT
Arotinolol, a now alpha and beta bloking agent, was administered orally in 32 hypertensive patients for 8 weeks in order to evaluate the antihypertensive effects and side effects. The doses were from 20mg to 30mg a day. The serum chemistries and chest X-ray were taken before and after Arotinolol administration. The results were as follows; 1) Blood pressure which was measured in sitting, supine and standing position was 176.37+/-4.73/116.54+/-4.34, 170.14+/-5.35/103.12+/-3.67, 156.37+/-7.54/104.31+/-3.34mmHg in control and 144.63+/-2.78/94.41+/-2.87, 146.47+/-5.41/89.12+/-4.34, 140.71+/-4.47/89.73+/-3.71mmHg in the treatment group. The differences between both blood pressure were statistically significant(P<0.001). 2) There was no significant change in pulse rate before and after medication. 3) There was no significant change in the laboratory findings such as CTR, GOT, GPT, alkaline phosphatase, CPK, creatinine, BUN, uric acid, cholesterol, fasting blood sugar and triglyceride before and after treatment. 4) The side effects of arotinolol were observed in 6 of 32 cases(18.7%), which were not required discontinuing the medication or decreasing the dose.
Subject(s)
Humans , Alkaline Phosphatase , Blood Glucose , Blood Pressure , Cholesterol , Creatinine , Fasting , Heart Rate , Hypertension , Thorax , Triglycerides , Uric AcidABSTRACT
Arotinolol, a new alpha and beta receptor antagonist, was administered in 27 essential hypertensive patients for 8 weeks in order to evaluate the antihypertensive effect and side effects. The dose were 10mg to 15mg given twice a day. The results are as follows : 1) Before medication, systolic and diastolic blood pressure in sitting, supine and erect position were 173.1+/-3.2/105.8+/-1.8, 171.1+/-3.6/86.7+/-2.0 and 169.3+/-2.6/97.2+/-2.1mmHg. 2) After 8 weeks treatment moderated to marked antihypertensive effect was observed in 74.0%(in systolic blood pressure) and 81.4%(in diastolic blood pressure) respectively in sitting position. 3) There was a significant reduction of pulse rate from 73.0+/-2.5 beats per minute on the beginning of the treatment to 63.4+/-5.2 beats per minute after 8 weeks of medication. 4) There was no significant change in hematocrit, WBC, serum lipid, GOT, GPT, BUN and creatinine. But fasting blood sugar was reduced from 95.3mg% to 81.5mg% with treatment. 5) The side effects of arotinolol were gastrointestinal symptoms(15%), fatigue(11%), dizziness(7%) and insomnia(3%). But these side effects were not severe enough to discontinue medication. In summary, arotinolol seemed to be an effective antihypertensive drug in treating mild to moderate hypertension without significant side effects.